SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial
SELLAS Life Sciences Group, Inc. has reached the 80th clinical event in its ongoing Phase 3 REGAL trial of galinpepimut-S (GPS) for the treatment of acute myeloid leukemia (AML).
Stocks · News reference
SELLAS Life Sciences Says Three Abstracts Evaluating SLS009, Potent, Selective CDK9 Inhibitor, In Preclinical Models Of PDAC Accepted For Poster Presentation At AACR Conference On Pancreatic Cancer
- Three posters to highlight preclinical activity of SLS009 (tambiciclib) across patient-derived KRAS mutant organoid models of pancreatic cancer – - Studies conducted in collaboration with the University of
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
SELLAS Life Sciences Announces Preclinical Data Demonstrating SLS009 Synergy And Activity In MYC-Amplified Pancreatic Cancer Models
SLS Stock Looks Like a $3 Billion Biotech Winner—This Short Seller Says the Market Has It Dangerously Wrong: 'Most Expensive Coin Flip' (UPDATED)
Short seller BMF Capital disclosed a short position in SELLAS Life Sciences, arguing the market has 'dangerously overvalued' the biotech.